TGen identifies compound that could improve drug development against deadly brain cancer

A study led by scientists at TGen has identified ‘a potent inhibitory compound’ in the elusive hunt for an improved treatment against glioblastoma, the most common and deadly type of adult brain cancer. Aurintricarboxylic Acid (ATA) is a chemical compound that in laboratory tests was shown to block the chemical cascade that otherwise allows glioblastoma cells to invade normal brain tissue and resist both chemo and radiation therapy, according to a TGen-led report published today in the scientific journal Oncotarget.
Go to Source